NEW YORK--(BUSINESS WIRE)--Americord, the fastest growing cord blood bank in the country, is reinforcing its commitment to providing state-of-the-art umbilical cord blood, cord tissue, and placenta tissue banking to its clients by securing additional capacity at a second cyropreservation laboratory.
With significantly more resources for processing and storage, Americord is now positioned for its next phase of growth. The combination of two world-class facilities allows the company to meet emerging client needs and accelerates product development for even better patient outcomes.
“As Americord continues to grow, our dedication to clients remains unchanged,” said CEO Martin Smithmyer. “We have aligned ourselves with the most innovative labs in the cord blood banking industry to ensure expanding families receive the best possible products and services.”
Americord has thoroughly vetted both facilities to ensure they meet all regulatory requirements and conform to Americord’s standards of operating excellence.
About Americord Registry (“Americord”)
Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company’s laboratories are CLIA Certified, accredited by the AABB and comply with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. For more information, visit www.americordblood.com.